3 results
Approved WMOCompleted
The primary study objective is to assess the effect of lanreotideAutogel 120mg administered every 28 days compared to placebo, onprogression-free survival in patients with well or moderatelydifferentiated non functioning entero-pancreatic endocrine…
Approved WMOCompleted
To investigate the efficacy of lanreotide therapy as compared to placebo in patients with NFMA and positive pituitary somatostatin receptor imaging using Gallium-68 DOTATATE PET/CT, on tumor size.
Approved WMOPending
Primary objective: 1. Determine difference in stone expulsion rate with -and without Tamsulosin Secondary objectives: 1. Time to stone expulsion2. Stone expulsion rate in patients with cholangitis with -and without Tamsulosin3. Adverse events 4.…